Related Experiment Video

Updated: Jun 17, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication

Ommoleila Molavi1, Abdullah Mahmud, Samar Hamdy

  • 1Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, T6G 2N8, Canada.

Molecular Pharmaceutics
|December 25, 2009
PubMed

Insights

New polymeric nanoparticles deliver STAT3 inhibitor JSI-124 to tumors and immunosuppressed dendritic cells (DCs), enhancing cancer immunotherapy by overcoming immunosuppression.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Constitutively activated Signal Transducer and Activator of Transcription-3 (STAT3) in tumor and dendritic cells (DCs) drives immunosuppression, hindering cancer immunotherapy.
  • Targeting STAT3 in tumor cells and DCs is crucial for overcoming this immunosuppressive tumor microenvironment.

Purpose of the Study:

  • To develop a polymeric nanocarrier for targeted delivery of the STAT3 inhibitor JSI-124 to tumor cells and immunosuppressed DCs.
  • To evaluate the efficacy of JSI-124-loaded nanoparticles in vitro for cancer treatment and immune modulation.

Main Methods:

  • JSI-124 was chemically conjugated to poly(d,l-lactic-co-glycolic acid) (PLGA) to form PLGA-JSI-124 conjugate nanoparticles (NPs) via emulsification solvent evaporation.
  • Characterization involved thin layer chromatography, (1)H NMR, and liquid chromatography-mass spectrometry for JSI-124 conjugation and quantification.
  • In vitro studies assessed anticancer and STAT3 inhibitory activity in B16 melanoma cells and evaluated NP effects on p-STAT3 levels and function of immunosuppressed DCs (B16CM-DCs) using mixed lymphocyte reaction (MLR).

Main Results:

  • PLGA-JSI-124 NPs demonstrated controlled release of JSI-124 over one month and comparable in vitro anticancer and STAT3 inhibitory activity to soluble JSI-124.
  • NPs effectively suppressed p-STAT3 in B16CM-DCs, restoring their function.
  • Co-administration of PLGA-JSI-124 NPs and CpG-loaded NPs significantly enhanced T cell proliferation in MLR compared to single treatments.

Conclusions:

  • PLGA NPs provide a viable platform for sustained release and targeted delivery of JSI-124 to tumors and immunosuppressed DCs.
  • This approach holds potential for modulating anticancer responses by targeting both tumor cells and immune cells to enhance cancer immunotherapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.